Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02024243 · ClinicalTrials.gov registry record

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

A clinical trial, sponsored by Chandan Sen.

Terminated
Registry status
54
Enrollment target

NCT02024243 is a clinical trial that was terminated before completion, run by Chandan Sen. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02024243 was terminated before completion, sponsored by Chandan Sen.

TERMINATED
Registry status
54 participants
Enrollment target

Study Summary

Hypothesis: Elevated miR210 in the epidermis (outer layer of skin) of ischemic human wound edge tissue (tissue that has a lack of blood flow to it) is associated with poor healing outcome in a setting of standard clinical care. Aim of the study: To determine whether elevated miR-210 in the epidermis of ischemic human wound edge tissue is associated with poor healing outcome in a setting of standard clinical care. This study will last 14 weeks. Adult patients, who are non-diabetic or tightly controlled diabetic, and, who have chronic venous leg ulcers that have been open/not healed for at least 12 weeks, will be enrolled in this study. Patients will be recruited from the Indiana University Health Comprehensive Wound Center (CWC). On days 0, 14 and 28, patients will have the following performed: measurements and photographs taken of their wound; TCOM (transcutaneous oxygen measurement) or ABI to measure the amount of oxygen in the wound tissue, if receiving a tissue biopsy; and two 3-mm punch biopsies from the same wound/ulcer. Biopsies will not be taken if the wound has closed by day 14 or day 28. Additionally, patients' medical records will be reviewed throughout the study for 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed. ABI will be completed per study personnel at initial visit for all consented subjects to ensure subject eligibility (as listed TCOM\<30 mmHg in exclusion criteria). If ABI's are unable to be obtained, TCOM will be performed. There will be a total of 5 visits for this study (6 total visits for patients with open wounds on day 28 of the study). Visits will occur on days 0, 7, 14, 21,28.

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2015-10-01
Est. Completion 2023-03-08

Sponsor

Chandan Sen

2 total trials

What the Registry Record Tells You About NCT02024243

The ClinicalTrials.gov registry entry for NCT02024243 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chandan Sen, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02024243 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02024243 about?

NCT02024243 is a clinical study titled "Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing". Hypothesis: Elevated miR210 in the epidermis (outer layer of skin) of ischemic human wound edge tissue (tissue that has a lack of blood flow to it) is associated with poor healing outcome in a setting of standard clinical care. Aim of the study: To determine whether elevated miR-210 in the epidermi...

What is the current status of trial NCT02024243?

This trial is currently terminated. The enrollment target is 54 participants. The study started on 2015-10-01. Estimated completion is 2023-03-08.

Who is sponsoring clinical trial NCT02024243?

This trial is sponsored by Chandan Sen, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.